HGH 191AA (Injectable) dosing

What it is

HGH 191aa is a lab-made copy of human growth hormone, also called somatropin. The "191aa" means it has the same 191 building blocks (amino acids) as the hormone your own pituitary gland makes. Your body cannot tell the difference between the two.

Growth hormone drives growth in childhood, but adults still need it. It helps build and keep muscle, break down fat, repair cells and keep metabolism running well. Your body releases it in bursts, with the biggest burst during deep sleep.

It is made by bacteria that have been modified to produce the human protein. Prescription brands include Genotropin, Norditropin, Humatrope and Saizen. These are approved for conditions such as growth hormone deficiency in children and adults, Turner syndrome, chronic kidney failure, Prader-Willi syndrome and HIV-related wasting. Research-grade HGH 191aa is also sold by peptide suppliers.

This is the original growth hormone compound. When people talk about "growth hormone" in bodybuilding or anti-ageing, this is what they mean. Peptides such as CJC-1295 and ipamorelin exist because HGH itself was expensive and hard to get for decades.

HGH 191aa is recombinant human growth hormone (somatropin), a 191-amino-acid protein that is sequence-identical to the endogenous hormone secreted by the anterior pituitary. It is produced by recombinant DNA technology, typically in genetically modified E. coli, yielding a bioidentical molecule with the same receptor binding and downstream signalling as native GH.

Growth hormone regulates linear growth in childhood and, in adults, protein synthesis, lipid metabolism, lean mass maintenance, cellular repair and broader metabolic function. Secretion is pulsatile, with the largest pulse occurring shortly after sleep onset.

Pharmaceutical somatropin (Genotropin, Norditropin, Humatrope, Saizen) is approved for paediatric and adult growth hormone deficiency, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome and HIV-associated wasting. Research-grade HGH 191aa is distributed through peptide suppliers.

HGH is the reference compound for the entire growth hormone category. Secretagogues such as CJC-1295, ipamorelin and tesamorelin were developed to stimulate endogenous release of this hormone, and their pharmacology is only meaningful relative to what exogenous somatropin does directly.

Unit conversion: 1 mg of somatropin is approximately 3 IU, varying slightly by product.

How it works

Growth hormone works in two ways: directly and through a second messenger called IGF-1.

Normally, your brain sends signals to the pituitary gland telling it when to release growth hormone and how much. The hormone then travels to the liver, which responds by making IGF-1. IGF-1 does most of the heavy lifting: muscle repair, cell repair, recovery and collagen production.

When you inject HGH, it goes straight into the blood and attaches to growth hormone receptors on cells. Directly, it tells fat cells to release stored fat (especially belly fat), helps cells take in protein building blocks, and raises blood sugar slightly. Indirectly, it tells the liver to make IGF-1, which builds muscle, bone and cartilage.

Your liver needs insulin around to turn growth hormone into IGF-1 efficiently. So timing food matters. Inject before bed on an empty stomach and you get more fat burning. Inject in the morning and eat 30 minutes later and more of it becomes IGF-1 for muscle.

The big catch: injecting HGH skips your body's control system. Your body sees high levels and tells the pituitary to slow down. Over time your own production drops, the same way testosterone injections shut down natural testosterone. Peptides like CJC-1295 and ipamorelin keep that control system working; HGH does not.

Injected HGH stays raised for several hours (about 2 to 4 hours for half of it to clear) and then returns to baseline.

Endogenous GH release is governed by hypothalamic GHRH (stimulatory, controlling pulse timing), somatostatin (inhibitory) and gastric ghrelin acting through a separate receptor (controlling pulse amplitude). Combined GHRH and ghrelin signalling produces a synergistic pituitary response far larger than either alone. Released GH acts on the liver to generate IGF-1, which mediates most anabolic effects: muscle protein synthesis, cellular repair, recovery and collagen production.

Exogenous somatropin binds the growth hormone receptor on target cells and activates the JAK-STAT pathway. Janus kinases phosphorylate STAT proteins, which translocate to the nucleus and upregulate gene transcription, increasing protein synthesis and cellular growth. Direct GH effects include lipolysis via hormone-sensitive lipase activation, increased amino acid uptake, increased protein synthesis and anti-insulin effects that raise blood glucose. GH preferentially mobilises visceral adipose tissue.

Indirect effects run through hepatic IGF-1 production. IGF-1 binds its own receptor and drives muscle protein synthesis, bone growth and mineralisation, cartilage growth and tissue regeneration. Hepatic GH-to-IGF-1 conversion is insulin-dependent, so nutrient timing relative to injection shifts the balance between lipolytic and anabolic outcomes.

The critical distinction from secretagogues is feedback bypass. Exogenous GH elevates circulating GH and IGF-1, triggering somatostatin release that suppresses pituitary responsiveness to GHRH. Research showed that after a single exogenous GH injection, GHRH-pathway compounds such as CJC-1295 and tesamorelin were inhibited by 86%, and ghrelin-pathway compounds such as ipamorelin were blunted by about 32%. Over time endogenous production declines, analogous to HPTA suppression under exogenous testosterone. Secretagogues preserve the feedback loop and impose a physiological ceiling; direct GH has none.

Native secretion is pulsatile, which matters for receptor sensitivity. Subcutaneous somatropin produces an elevation lasting several hours, with a half-life of approximately 2 to 4 hours, so injection timing and frequency can be tuned to emphasise specific effects.

What it does

HGH changes body composition slowly and steadily. It helps burn fat, particularly the deep belly fat around the organs, and helps build and protect muscle. It speeds up repair of tissues, including tendons, ligaments and cartilage, and many users notice deeper sleep and faster recovery from training.

Over a few months it also thickens skin, improves hair and nails, and supports bone density.

At replacement doses (1 to 2 IU daily), a 6-month trial in older men found an 8.8% rise in lean mass, a 14.4% drop in fat, a 7.1% increase in skin thickness and a 1.6% increase in spine bone density. A large review found that in healthy older adults the gains were modest, roughly 2 kg more lean mass and 2 kg less fat, and came with more swelling, joint pain and blood sugar problems.

The main downside is that HGH raises blood sugar and suppresses your own growth hormone production. It works best for people with proven deficiency; for healthy adults the benefits are real but modest.

HGH is potently lipolytic, activating hormone-sensitive lipase and preferentially reducing visceral adipose tissue. It increases protein synthesis and nitrogen retention, is muscle-sparing during caloric restriction, accelerates tissue repair through IGF-1-mediated collagen synthesis, and supports bone mineral density. Users frequently report improved sleep architecture consistent with the nocturnal GH pulse.

Rudman et al. (1990) reported, at roughly 2 IU daily over 6 months in men over 60 with low IGF-1, an 8.8% increase in lean body mass, a 14.4% decrease in adipose tissue, a 7.1% increase in skin thickness and a 1.6% increase in lumbar vertebral bone density. Liu et al. (2007) found small body composition changes in healthy elderly adults (approximately 2 kg lean mass gain, 2 kg fat loss) without gains in strength or aerobic capacity, suggesting part of the lean mass change is fluid, alongside increased soft tissue oedema, carpal tunnel syndrome, arthralgias, gynaecomastia and impaired glucose tolerance.

In documented GHD, Gotherstrom et al. (2009/2010) showed sustained improvements in body composition and muscle strength over 10 years, and Carel et al. (2022) found no excess de novo cancer incidence across 15,809 treated patients (SIR 0.92, 95% CI 0.83 to 1.01). Knuppel et al. (2023) described a U-shaped relationship between IGF-1 and mortality, supporting a moderate target range rather than maximal elevation.

Benefits

Evidence grades: what the labels mean

Human trials Supported by randomised or placebo-controlled human trials.
Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
Animal or lab only Shown in animal or cell studies only; not yet tested in people.
Anecdotal No published studies; based on user reports or theory.

Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.

Fat loss, especially deep belly fat; a 6-month trial showed a 14.4% drop in fatHuman trials
Muscle growth and protection; the same trial showed an 8.8% rise in lean massHuman trials
Faster recovery between workouts and better healing of tendons, ligaments and cartilageLimited human data
Deeper, more restful sleep, often the first change users noticeAnecdotal
Thicker skin, fewer wrinkles and better hair and nails after 2 to 3 monthsAnecdotal
Stronger bones; a 1.6% increase in spine bone density over 6 monthsHuman trials
Helps keep muscle while dietingLimited human data

Lipolysis via hormone-sensitive lipase with preferential visceral fat reduction; 14.4% decrease in adipose tissue over 6 months (Rudman et al., 1990)Human trials
Increased protein synthesis and nitrogen retention; 8.8% increase in lean body mass over 6 months, noting Liu et al. (2007) found no strength or aerobic capacity gain in healthy adultsHuman trials
Muscle-sparing effect during caloric restrictionLimited human data
Accelerated tissue repair and IGF-1-driven collagen synthesis in tendon, ligament and cartilageLimited human data
Improved sleep quality consistent with the nocturnal GH pulseAnecdotal
Skin thickness (7.1% increase), elasticity, hair and nail quality after 2 to 3 monthsAnecdotal
Bone mineral density; 1.6% increase in lumbar vertebral density over 6 months, with sustained gains over 10 years in GHD (Gotherstrom et al., 2009/2010)Human trials

What to expect

HGH works slowly. Do not expect big changes in 2 weeks; the real results take months.

Weeks 1 to 4: Better sleep is usually the first thing you notice. Expect some water retention in the hands and face, and mild joint stiffness while your body adjusts. Energy may improve.

Weeks 4 to 8: Fat loss becomes visible, especially around the middle. Skin looks fuller. Recovery from training improves.

Months 2 to 3: Body shape changes become clear. Skin, hair and nails improve. Joints and connective tissue start to feel better.

Months 3 to 6: Peak body recomposition. Belly fat drops noticeably. Sleep, recovery and energy stay improved.

Months 6 and beyond: Slow, ongoing gains in bone density and connective tissue. Early side effects such as water retention and stiff joints have usually settled or been fixed by lowering the dose.

The 6-month Rudman trial at about 2 IU daily found an 8.8% gain in lean mass, a 14.4% fat loss, 7.1% thicker skin and 1.6% denser spine bone. The authors said these changes were the opposite of 10 to 20 years of ageing. Ten-year studies in people with growth hormone deficiency kept the benefits going at about 1 IU daily maintenance.

Effects develop gradually and the full profile takes months to emerge.

From clinical data: Rudman et al. (1990), 6 months at approximately 2 IU daily, produced an 8.8% increase in lean body mass, a 14.4% decrease in adipose tissue, a 7.1% increase in skin thickness and a 1.6% increase in lumbar bone density, changes the authors described as opposite to those seen across 10 to 20 years of ageing, without claiming to reverse ageing. Ten-year follow-up in GHD adults showed sustained body composition and strength improvements, with initial doses of approximately 2 IU daily typically reduced to approximately 1 IU daily for maintenance with minimal side effects.

In practice, users report:

Weeks 1 to 4: improved sleep quality first, with fluid retention in hands and face, mild joint stiffness and possible energy gains.

Weeks 4 to 8: noticeable fat loss, particularly midsection; fuller skin; improved training recovery.

Months 2 to 3: visible body composition change; skin, hair and nail improvements; early connective tissue benefits.

Months 3 to 6: peak recomposition with significant visceral fat reduction and sustained recovery, sleep and energy improvements.

Months 6 and beyond: continued gradual gains in bone density, connective tissue and composition, with initial oedema and arthralgia largely resolved or managed by dose adjustment.

On drugs.com, 62% of somatropin reviewers reported a positive experience. Common negative reports include water retention, carpal tunnel-like paraesthesia above 2 IU daily, transient lethargy and, at 4+ IU, insulin resistance and elevated glucose.

Reconstitution and dosing

HGH is measured in IU (international units). Roughly 3 IU equals 1 mg, though this varies a little by product. The 24 IU vial mixed with 1 mL of water gives 24 IU per mL, so 1 IU is 0.04 mL.

There are two very different ways to use it. Low doses of 1 to 2 IU daily replace what your body no longer makes enough of. Side effects are minimal. Doses of 4 IU and above push levels past anything your body ever made naturally; results are bigger but so are the side effects.

Anti-ageing and wellness: 1 to 2 IU daily, 5 to 7 days a week, before bed or first thing in the morning on an empty stomach. Run long term or cycle 6 months on, 2 months off.

Body recomposition: 2 to 4 IU daily, ideally split between morning and afternoon or evening, for at least 3 to 6 months.

Working up: start at 1 to 2 IU daily for weeks 1 to 2, move to 2 to 3 IU for weeks 3 to 4 if you feel fine, and only go to 3 to 4 IU from week 5 if your goals need it.

Timing: morning on an empty stomach favours fat burning; stay fasted for a couple of hours afterwards. Before bed copies your natural night-time release and helps sleep. For muscle, inject fasted and eat 30 to 60 minutes later. At 4 IU or more, split into morning and evening doses to reduce side effects.

Studied doses: the Rudman trial used 0.03 mg/kg three times a week (about 2 IU daily); the 10-year Gotherstrom study started at 0.72 mg/day (about 2 IU) and dropped to 0.37 mg/day (about 1 IU). Most anti-ageing trials used 1 to 3 IU daily.

For most people wanting to bring IGF-1 into a healthy range (120 to 175 ng/mL), peptides such as CJC-1295 with ipamorelin are the safer first choice because your body keeps a natural ceiling. HGH makes sense if you have diagnosed deficiency, if peptides failed after fixing thyroid and sex hormones, or if you knowingly want above-normal levels.

Reconstitution: 24 IU vial in 1 mL bacteriostatic water yields 24 IU/mL; 1 IU is 0.04 mL. Conversion: 1 mg somatropin is approximately 3 IU, varying slightly by product.

Studied doses: Rudman et al. used 0.03 mg/kg three times weekly, roughly 2 IU daily for an average adult. Gotherstrom et al. started at approximately 0.72 mg/day (roughly 2 IU) and reduced to 0.37 mg/day (roughly 1 IU) for long-term maintenance. Liu et al. noted most anti-ageing trials used the equivalent of 1 to 3 IU daily.

Dose tiers: 1 to 2 IU daily is physiological replacement with minimal side effects. 4+ IU daily is supraphysiological enhancement with proportionally greater fluid retention, arthralgia, carpal tunnel symptoms and insulin resistance. Bodybuilders commonly use 4 to 8+ IU daily, a range not studied in healthy ageing.

Anti-ageing and wellness: 1 to 2 IU daily, 5 to 7 days per week, before bed or morning fasted, long term or cycled 6 months on, 2 months off.

Body recomposition: 2 to 4 IU daily, split dosing preferred (morning plus afternoon/evening), 3 to 6 months minimum.

Progression: weeks 1 to 2 at 1 to 2 IU daily; weeks 3 to 4 at 2 to 3 IU daily if tolerated; week 5 onward at 3 to 4 IU daily if required for goals.

Timing: morning fasted maximises lipolysis while insulin is low; remaining fasted for a couple of hours lets GH act directly on lipid metabolism. Pre-bed dosing mimics the nocturnal pulse and supports sleep and recovery. For anabolic emphasis, inject fasted and eat 30 to 60 minutes later so postprandial insulin supports hepatic IGF-1 conversion. At 4+ IU, splitting into morning and evening injections reduces side effects and improves utilisation.

Monitoring: IGF-1 at baseline, 4 to 6 weeks and every 3 months, targeting 120 to 175 ng/mL for optimisation; fasting glucose and HbA1c at baseline and every 3 months; thyroid panel (free T3, free T4, TSH) at baseline and every 6 months; comprehensive metabolic panel.

Selection: exogenous GH has no feedback ceiling and suppresses pituitary response to secretagogues (86% GHRH-pathway inhibition, about 32% ghrelin-pathway blunting), so combining with CJC-1295, ipamorelin or tesamorelin is pharmacologically pointless. HGH is indicated for documented GHD, for non-response to secretagogues after thyroid and sex hormones are addressed, or for deliberately supraphysiological goals with accepted risk.

Standard, 24 IU vial

Mix with 1 mL (100 units) of bacteriostatic water.

0.24 IU per unit

Cycle: 3 to 6 months minimum; long-term or 6 months on, 2 months off · Frequency: Daily, 5 to 7 days per week; split morning and evening at 4 IU or above

When	Dose	Draw	How often
Week 1 to 2	1 to 2 IU	4.17 units	once daily
Week 3 to 4	2 to 3 IU (if tolerated)	8.33 units	once daily
Week 5+	3 to 4 IU (if needed for goals)	12.5 units	once daily or split morning and evening

The calculator works in milligrams; this compound is dosed in IU, use the table.

Who should avoid it

Anyone with active cancer, an active tumour, or a past cancer diagnosis. Growth hormone tells cells to grow, so speak to your cancer doctor before even considering it.
Anyone with diabetic eye disease (diabetic retinopathy).
Anyone who is acutely and seriously ill, for example after major surgery or in intensive care.
Use great care if you have diabetes or pre-diabetes. HGH raises blood sugar and makes insulin work less well.
Use care if you have heart disease, a history of carpal tunnel syndrome, a thyroid condition (HGH can bring hidden low thyroid to the surface), or liver disease (the liver turns growth hormone into IGF-1).
If you take insulin or diabetes tablets, your blood sugar control will change and your medicine may need adjusting. Steroid tablets (glucocorticoids) can make HGH work less well, and thyroid medicine doses may need changing.
Do not start without blood tests. IGF-1, fasting glucose, HbA1c and thyroid tests before you begin, then repeated on a schedule, are essential rather than optional.

Active malignancy, active tumours, or any history of malignancy: GH and IGF-1 are mitogenic and anti-apoptotic; oncology consultation is required before use, and the compound is contraindicated where disease is active.
Diabetic retinopathy: an absolute contraindication in the somatropin labelling.
Acute critical illness: GH therapy in acutely ill patients is contraindicated.
Diabetes or pre-diabetes: GH exerts direct anti-insulin effects, raising fasting glucose and impairing glucose tolerance; it can unmask or worsen diabetes. Insulin or oral hypoglycaemic doses may require adjustment.
Cardiovascular disease: fluid retention, blood pressure elevation and, with chronically elevated IGF-1, cardiac hypertrophy are all relevant risks.
History of carpal tunnel syndrome: soft tissue oedema around the median nerve is one of the most consistent adverse events in the trial literature.
Thyroid disease: GH accelerates peripheral T4 to T3 conversion and can lower free T4, unmasking central hypothyroidism; thyroid replacement doses may need revising.
Hepatic disease: hepatic IGF-1 generation is the main indirect effector pathway, so liver dysfunction alters both response and monitoring.
Concurrent glucocorticoids: attenuate the anabolic and metabolic response to GH.
Mandatory monitoring: IGF-1 at baseline, 4 to 6 weeks, then every 3 months (optimisation target 120 to 175 ng/mL); fasting glucose and HbA1c at baseline and every 3 months; free T3, free T4 and TSH at baseline and every 6 months; a comprehensive metabolic panel for hepatic and renal function.

Side effects

Water retention, especially in the hands, face and ankles, and mostly in the first few weeks.
Stiff or aching joints while the body adjusts. This usually settles with time or a lower dose.
Numbness and tingling in the hands (carpal tunnel symptoms), more likely above 2 IU a day.
Redness or soreness where the injection goes in.
Higher blood sugar and reduced sensitivity to insulin. This is the most important long-term side effect and is why regular blood sugar tests matter.
Lower thyroid hormone (free T4). Some users need thyroid support while on HGH.
Tiredness during the first weeks, mood changes, more sweating, and raised blood pressure from fluid retention.
Breast tissue growth in men (gynaecomastia).
At high doses (4 IU or more) used for a long time: enlargement of internal organs such as the heart and gut, enlarged jaw, hands and feet, and a higher risk of heart problems from long-term high IGF-1.
Side effects at 1 to 2 IU are usually mild and fade or respond to a dose cut. At 4 IU and above they tend to persist and need active management.

Fluid retention and soft tissue oedema, most pronounced in the initial weeks; secondary hypertension is reported in practice.
Arthralgia and joint stiffness, typically resolving with dose adjustment.
Carpal tunnel syndrome from median nerve compression, more frequent above 2 IU daily; Liu et al. (2007) found significantly higher rates of oedema, carpal tunnel syndrome and arthralgias versus placebo.
Injection site reactions.
Insulin resistance and hyperglycaemia via GH's direct anti-insulin action; impaired glucose tolerance was documented in the Liu et al. (2007) review and this is the most clinically significant adverse effect for long-term use.
Reduced free T4 through altered thyroid hormone metabolism, potentially unmasking hypothyroidism.
Gynaecomastia, significantly more frequent than placebo in the Liu et al. (2007) pooled data.
Lethargy during the adjustment period, mood changes and increased sweating are reported by users.
At 4+ IU or prolonged supraphysiological exposure: visceromegaly (intestinal growth, cardiac hypertrophy), acromegaloid changes in the jaw, hands and feet at extreme doses over long periods, and elevated cardiovascular risk from chronically raised IGF-1.
Suppression of endogenous pituitary GH output via somatostatin-mediated negative feedback, with GHRH-pathway secretagogue responses inhibited by 86% and ghrelin-pathway responses blunted by about 32% after a single exogenous GH injection.

What the evidence shows

HGH is the most studied compound in the growth hormone space, with decades of clinical research behind it.

The landmark trial is Rudman et al. (1990), published in the New England Journal of Medicine. Twelve men over 60 with low IGF-1 took HGH for 6 months at a dose roughly equal to 2 IU a day. Lean body mass rose 8.8%, fat mass fell 14.4%, skin thickness rose 7.1% and lower spine bone density rose 1.6%. The authors said these changes were the opposite of what 10 to 20 years of ageing does, but they were careful not to claim they had reversed ageing.

Liu et al. (2007) pooled every good trial in healthy older adults. HGH added about 2 kg of lean mass and removed about 2 kg of fat, but it did not improve strength or fitness, and it caused more swelling, carpal tunnel, joint pain, breast tissue growth in men and blood sugar problems. The review said HGH could not be recommended for anti-ageing on the evidence.

Gotherstrom et al. (2009/2010) followed adults with true growth hormone deficiency for 10 years. Strength and body composition improved and stayed improved, with the dose dropping from roughly 2 IU to roughly 1 IU a day for maintenance. Carel et al. (2022) reviewed 15,809 treated patients and found new cancer rates no higher than the general population.

Knuppel et al. (2023) showed that both very low and very high IGF-1 raise the risk of death. The middle range, about 120 to 175 ng/mL, looks safest. Samaras et al. (2025) concluded that HGH clearly helps people who are deficient, but its value in healthy older adults remains controversial.

What this means for you: if you are genuinely deficient, HGH has strong support. If you are healthy and want to look or feel younger, the gains are real but modest, and the side effects are not.

HGH 191aa carries the deepest evidence base of any compound in the somatotropic category.

Rudman et al., 1990 (N Engl J Med) treated 12 men over 60 with low IGF-1 at 0.03 mg/kg three times weekly, roughly 2 IU daily, for 6 months. Lean body mass increased 8.8%, adipose tissue decreased 14.4%, skin thickness increased 7.1% and lumbar vertebral bone density increased 1.6%. The authors described the changes as opposite to those of 10 to 20 years of ageing while explicitly declining to claim ageing reversal.

Liu et al., 2007 (Ann Intern Med) systematically reviewed RCTs of GH in healthy elderly adults. Body composition shifted by approximately 2 kg in lean mass and 2 kg in fat mass, with no gain in muscle strength or aerobic capacity, suggesting part of the lean mass change was fluid. Adverse events, including soft tissue oedema, carpal tunnel syndrome, arthralgias, gynaecomastia and impaired glucose tolerance, were significantly more common. The review concluded GH cannot be recommended as anti-ageing therapy.

Gotherstrom et al., 2009/2010 (J Clin Endocrinol Metab): a 10-year prospective study of GH replacement in adult GHD. Sustained gains in muscle strength and body composition; initial dosing of approximately 0.72 mg/day (roughly 2 IU) reduced to 0.37 mg/day (roughly 1 IU) for maintenance, with long-term safety in the GHD population.

Carel et al., 2022 (J Clin Endocrinol Metab): safety overview of 15,809 GH-treated patients. De novo cancer incidence matched the general population (standardised incidence ratio 0.92, 95% CI 0.83 to 1.01), with neither adult-onset nor childhood-onset GHD associated with increased risk.

Knuppel et al., 2023 (EPIC-Heidelberg, J Clin Endocrinol Metab): a U-shaped relationship between circulating IGF-1 and mortality from cancer, cardiovascular disease and all causes, supporting a moderate target range of 120 to 175 ng/mL rather than maximal IGF-1.

Samaras et al., 2025 (Front Aging): GH therapy is well supported in GHD, while its safety, efficacy and role in healthy elderly individuals remains highly controversial, with small body composition gains offset by increased adverse events.

The net position: clear benefit in documented GHD; real but modest benefit with a dose-dependent adverse effect burden in healthy adults using it for anti-ageing or body composition.

User reports

From public forums

Reports gathered from Reddit, drugs.com reviews and bodybuilding forums paint a consistent picture, though this is anecdotal and does not carry the weight of published trials.

On the positive side, users report better body composition over 3 to 6 months, with fat loss around the midsection the most noticed change. Deeper, more restful sleep is one of the most commonly mentioned benefits and often the first thing people notice, usually in weeks 1 to 4. Faster recovery from training and injuries is reported often. Improvements in skin, hair and nails tend to show up after 2 to 3 months. On drugs.com, 62% of somatropin reviewers reported a positive experience.

On the negative side, water retention is the number one complaint, especially in the first few weeks. Joint stiffness and carpal tunnel-type numbness in the hands are common, particularly above 2 IU a day. Some users feel tired during the first weeks. At 4 IU and above, high blood sugar and insulin resistance become more common. Cost is a constant concern because HGH is expensive and has to be used long-term.

Where real use differs from the research: bodybuilders often run 4 to 8+ IU a day, far above anything studied in healthy adults. At those doses, insulin resistance, heavy fluid retention, joint pain and organ growth become genuine risks. Some combine HGH with insulin, which carries a serious and potentially fatal low blood sugar risk and has no safety data. Some clinics prescribe low-dose HGH alongside CJC-1295 or ipamorelin, but in practice the HGH blocks the peptides from working, so the money spent on them is wasted.

Aggregated reports from Reddit, drugs.com and bodybuilding forums are anecdotal but directionally consistent with the trial literature at replacement doses and diverge sharply at performance doses.

Positive reports. Users consistently describe improved body composition over 3 to 6 months, with preferential loss of midsection and visceral fat. Sleep quality improvement, typically within the first 4 weeks, is among the most cited effects, consistent with the nocturnal GH pulse. Faster recovery from training and injuries, and improved skin, hair and nail quality after 2 to 3 months, are widely reported. On drugs.com, 62% of somatropin reviewers reported a positive experience.

Negative reports. Fluid retention dominates early complaints. Joint stiffness and carpal tunnel-like paraesthesia are frequent above 2 IU daily. Lethargy during the adjustment period, mood changes, elevated blood pressure secondary to fluid retention and increased sweating are also reported. At 4+ IU, insulin resistance and elevated fasting glucose become common. Ongoing cost is a persistent theme.

Divergence from the evidence. Bodybuilders commonly use 4 to 8+ IU daily, well beyond the 1 to 3 IU range that most anti-ageing studies employed. At supraphysiological doses the adverse profile shifts toward insulin resistance, marked oedema, arthralgia and visceromegaly. Co-administration with insulin to offset GH's anti-insulin action and enhance hepatic IGF-1 generation is an advanced practice with serious hypoglycaemia risk and no published safety data. Clinic protocols pairing low-dose HGH with secretagogues are pharmacologically incoherent: exogenous GH triggers somatostatin release that suppresses the pituitary response to GHRH and ghrelin analogues, so the secretagogues contribute little.

User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.

Stacking

Testosterone (TRT)
No known clash. The two work on different hormone systems, and testosterone helps muscle tissue make more IGF-1, which may strengthen HGH's effects. Many anti-ageing protocols combine both.
No direct interaction concern. Testosterone upregulates intramuscular IGF-1 expression, so it can potentiate the downstream anabolic effects of circulating GH. Complementary and commonly paired in hormone optimisation protocols.
GLP-1 agonists (semaglutide, tirzepatide, retatrutide)
Different mechanisms, no known clash. GLP-1 drugs drive fat loss but can cost muscle along the way; HGH helps protect muscle, so the pair may complement each other. No studies have tested the combination.
Mechanistically independent. GLP-1 receptor agonists drive fat loss through appetite and metabolic effects, while GH is muscle-sparing under caloric restriction, potentially offsetting the lean mass loss seen with aggressive weight reduction. No published studies have examined the combination.
BPC-157
No known clash. BPC-157 makes tendon cells more responsive to growth hormone, so the two may work together for healing and recovery.
BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, which may amplify the local reparative effects of circulating GH on connective tissue. Distinct mechanisms, potentially synergistic for recovery.
TB-500
No known clash. TB-500 supports tissue repair through a separate route, so it can sit alongside HGH in a recovery-focused plan.
No interaction concern. TB-500 acts on actin regulation and cell migration, a pathway independent of GH/IGF-1 signalling, making it a complementary partner for tissue repair.
CJC-1295 / Ipamorelin
Do not combine. Injected HGH makes the body release somatostatin, the signal that stops the pituitary from responding to these peptides. They end up doing very little. Pick one approach or the other; some users switch to secretagogues during HGH off periods instead.
Contraindicated on mechanistic grounds. Exogenous GH raises GH and IGF-1, triggering somatostatin release that suppresses pituitary responsiveness. After a single exogenous GH injection, GHRH-pathway compounds were inhibited by 86% and ghrelin-pathway compounds blunted by about 32%. Running secretagogues alongside HGH to preserve pituitary function is not supported by the mechanism; their use belongs in off-cycle periods.
Tesamorelin
Do not combine. Like CJC-1295, tesamorelin works by asking the pituitary to release growth hormone, and injected HGH blocks that response.
A GHRH analogue subject to the same somatostatin-mediated suppression as CJC-1295, with GHRH-pathway output inhibited by 86% following exogenous GH. No meaningful additive effect while HGH is being administered.
IGF-1 LR3
A bodybuilding-only combination that is not suitable for health goals. Adding IGF-1 on top of HGH removes every natural safety check and raises the risk of low blood sugar and heart problems.
Stacking IGF-1 on top of exogenous GH bypasses the entire regulatory axis. Risks include hypoglycaemia, IGF-1 receptor desensitisation and elevated cardiovascular risk. Requires significant knowledge and monitoring and is not appropriate for health optimisation.
Insulin
An advanced bodybuilding practice used to offset HGH's blood sugar effects. Dangerous low blood sugar can be fatal. It has no place in a health-focused plan.
Used to counteract GH's anti-insulin effects and enhance hepatic IGF-1 conversion. Hypoglycaemia risk is serious and potentially fatal, and there is no published safety data. Excluded from optimisation protocols.

Common questions

What is the difference between HGH and secretagogue peptides like CJC-1295 and ipamorelin?

Secretagogue peptides ask your pituitary gland to release its own growth hormone. Your body still controls how much comes out, so there is a natural ceiling. HGH skips the pituitary and puts growth hormone straight into your blood. There is no ceiling, so you must manage the dose carefully.

Secretagogues (CJC-1295, ipamorelin, tesamorelin) act on GHRH or ghrelin receptors to stimulate endogenous pulsatile GH release while leaving the somatostatin feedback loop intact, capping output at pituitary capacity. Exogenous somatropin bypasses the axis entirely, producing unregulated GH exposure with no physiological ceiling, and suppresses endogenous production over time.

Does HGH shut down natural growth hormone production?

Yes. When your body senses the extra growth hormone and IGF-1, it releases somatostatin, a signal that tells the pituitary to slow down. Over time your own production falls, much like testosterone injections switch off natural testosterone. Some users cycle 6 months on and 2 months off, or use secretagogues in the off period, to help recovery.

Yes. Elevated GH and IGF-1 trigger hypothalamic somatostatin release, suppressing pituitary output; after a single exogenous GH injection GHRH-pathway responses were inhibited by 86% and ghrelin-pathway responses by about 32%. Endogenous secretion declines with continued use, analogous to HPG axis suppression under testosterone replacement. Cycling (6 months on, 2 months off) or secretagogue use during off periods is employed in practice to support recovery.

Can HGH be taken alongside secretagogue peptides?

No. Injected HGH blocks the pituitary from answering the peptides, so you would be paying for compounds that are not working. Choose one approach: peptides that work within your body's limits, or HGH that bypasses them.

No. Exogenous GH-induced somatostatin release blunts the pituitary response to secretagogues, rendering them largely inert. The two approaches are mutually exclusive: secretagogues operate within physiological limits, exogenous GH overrides them. Combining them adds cost without pharmacological benefit.

What IGF-1 level should be targeted?

Research shows a U-shaped curve. Below 120 ng/mL is linked to frailty and muscle loss; above 190 ng/mL is linked to higher cancer and heart risk. The sweet spot for long-term health looks to be 120 to 175 ng/mL. Bodybuilders on high doses go well past this on purpose; for health, staying in the middle is the goal.

Knuppel et al. (2023) demonstrated a U-shaped association between circulating IGF-1 and mortality from cancer, cardiovascular disease and all causes. Levels below 120 ng/mL correlate with frailty and sarcopenia; levels above 190 ng/mL with elevated oncological and cardiovascular risk. The optimisation target is 120 to 175 ng/mL, with IGF-1 checked at baseline, 4 to 6 weeks, then every 3 months.

When does HGH make more sense than peptides?

First fix the basics: food, sleep, training and body fat. Then check your thyroid, because the pituitary needs it to respond properly. Then check sex hormones, since testosterone in men and oestrogen in women affect IGF-1. If all of that is sorted and peptides still are not raising your IGF-1, or you have a diagnosed deficiency, HGH becomes the next step.

HGH is indicated with documented GHD, when secretagogues have failed to raise IGF-1 after thyroid status (required for pituitary receptor function) and sex hormones (testosterone in men, oestrogen in women, both of which modulate IGF-1 production) have been optimised, or when the goal is explicitly supraphysiological and the associated risks are accepted.

Why did elite bodybuilders choose HGH over peptides?

A competitor stepping on stage at 250 pounds and shredded needs more growth hormone than the pituitary can make. Peptides cannot get past that limit. Those athletes use 4 to 8 IU of pharmaceutical HGH a day and accept the risks. For someone chasing health and longevity, the trade-off is completely different.

Stage-level physiques require GH exposure beyond maximal pituitary secretory capacity, a biological ceiling that secretagogues cannot exceed. Competitors typically use 4 to 8 IU of pharmaceutical somatropin daily and accept the supraphysiological adverse profile. The risk-benefit calculus for health and longevity optimisation is entirely different.

Does the timing of the injection and meals matter?

Yes. Injecting in the morning on an empty stomach and staying fasted for a couple of hours favours fat burning. Injecting before bed copies the natural night-time pulse and helps sleep and recovery. For muscle building, inject fasted and eat 30 to 60 minutes later so the insulin from the meal helps the liver turn growth hormone into IGF-1.

Yes. Fasted morning administration maximises direct lipolysis via hormone-sensitive lipase while insulin is low; remaining fasted for a couple of hours preserves this. Pre-bed dosing mimics the nocturnal GH pulse. For anabolic goals, injecting fasted then eating 30 to 60 minutes later supplies the hepatic insulin required for efficient IGF-1 generation. At 4+ IU, splitting into morning and evening doses reduces adverse effects and improves utilisation.

References

This entry was written from additional reference material. Units are recomputed from the stated protocol.